Fresh Recalls

Ascend Laboratories recalls

10 recent recalls on record for Ascend Laboratories in connected official government data as of September 7, 2026 at 6:00 AM UTC.

Models with recalls

Amlodipine and Olmesartan Medoxomil Tablets (2)Ascend Laboratories (1)Dabigatran Etexilate Capsules (6)Minocycline Hydrochloride Extended-Release Tablets (1)

All Ascend Laboratories recalls

FDA Not Yet Classified · Drug · August 5, 2026

Dabigatran Etexilate Capsules recall — Ascend Laboratories, LLC

Failed impurity/degradation specification:12M Long-term Stability conditions (25 ¿2 ¿C/60 ¿5%RH), an OOS result observed in Related substance test analysis w.r.t Impurity II, Impur…

Official ID EVT-99421-191x326 · Official record ↗

FDA Class III · Drug · August 5, 2026

Dabigatran Etexilate Capsules recall — Ascend Laboratories, LLC

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Official ID D-0739-2026 · Official record ↗

FDA Class III · Drug · August 5, 2026

Dabigatran Etexilate Capsules recall — Ascend Laboratories, LLC

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Official ID D-0738-2026 · Official record ↗

FDA Class III · Drug · August 5, 2026

Dabigatran Etexilate Capsules recall — Ascend Laboratories, LLC

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Official ID D-0737-2026 · Official record ↗

FDA Class III · Drug · July 29, 2026

Dabigatran etexilate Capsules recall — Ascend Laboratories, LLC

Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testin…

Official ID D-0736-2026 · Official record ↗

FDA Class III · Drug · July 29, 2026

Dabigatran etexilate Capsules recall — Ascend Laboratories, LLC

Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testin…

Official ID D-0735-2026 · Official record ↗

FDA Class II · Drug · July 29, 2026

Amlodipine and Olmesartan Medoxomil Tablets recall — Ascend Laboratories, LLC

Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications

Official ID D-0712-2026 · Official record ↗

FDA Class II · Drug · June 17, 2026

Minocycline Hydrochloride Extended-Release Tablets recall — Ascend Laboratories, LLC

Failed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis

Official ID D-0597-2026 · Official record ↗

FDA Class II · Drug · June 10, 2026

Amlodipine and Olmesartan Medoxomil Tablets recall — Ascend Laboratories, LLC

Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications

Official ID D-0556-2026 · Official record ↗

FDA Class II · Drug · May 20, 2026

Ascend Laboratories recall — Ascend Laboratories, LLC

Failed Dissolution Specifications

Official ID D-0547-2026 · Official record ↗

Verify with the official sources:

Found something wrong or missing? Report a data error.

Compiled from official public-domain government data. Last checked September 7, 2026 at 6:00 AM UTC.